Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel reported receiving a grant of 365 shares of common stock as fully vested restricted stock. These shares represent director retainer fees that he chose to take in stock instead of cash, at no cash cost per share. The grant was calculated using an average Arteris trading price of $39.28 over a defined period, and Kunkel elected to defer the actual receipt of the shares, leaving his reported direct holdings at 74,695 shares after the award.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an award of 350 shares of common stock as fully vested restricted stock. According to the disclosure, this represents retainer fees she elected to take in stock instead of cash, valued using an average trading price of $39.28.
The grant was made on July 5, 2026 and brings her directly held position to 106,764 common shares. The filing also notes that she elected to defer the actual receipt of the shares, indicating this is structured as deferred equity compensation rather than an open-market purchase.
Arteris, Inc. director, President and CEO K. Charles Janac reported multiple sales of Arteris common stock on July 2, 2026. The Form 4 shows net sales of 203,588 shares at various weighted average prices between $34.20 and $43.51 per share.
According to the footnotes, a portion of the shares was sold to satisfy Mr. Janac’s tax liability from the release of restricted stock units under the company’s equity incentive plans, using mandatory “sell to cover” transactions rather than discretionary trades. Additional sales were made by Bayview Legacy, LLC under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
After these transactions, Mr. Janac continues to hold Arteris shares both directly and indirectly, including 56,252 shares held by the Charles and Lydia Janac Trust, 193,508 shares held directly, and 8,736,733 shares beneficially owned through Bayview Legacy, LLC.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 192,686 shares of Arteris common stock. The trades occurred on July 2, 2026 across eight transactions at weighted average prices between $34.77 and $43.24 per share. The filing notes that these sales were made pursuant to a Rule 10b5-1 trading plan adopted by Bayview’s manager, K. Charles Janac, on December 12, 2025, indicating the transactions were pre-scheduled rather than opportunistic.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported tax-driven sales of common stock. On July 2, 2026, he sold a total of 5,599 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these sales were executed solely to satisfy his tax liability from the release of restricted stock units under the company’s equity incentive plans. The transactions were mandated "sell to cover" trades and are described as non-discretionary for the reporting person.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 3,648 shares of common stock on July 2, 2026 in four open-market transactions at a price of $38.7779 per share.
According to the filing, these sales were made to satisfy the reporting person's tax liability from the release of restricted stock units and were mandated under the company’s equity incentive plans as "sell to cover" transactions, meaning they were not discretionary trades.
Arteris, Inc. VP and CFO Nicholas B. Hawkins reported routine tax-related share sales. On July 2, 2026, he sold a total of 5,377 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these transactions were mandated "sell to cover" sales to satisfy tax liabilities from the release of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary. After these sales, Hawkins directly owned 103,172 shares of Arteris common stock.
Company AIP notice of proposed sale of common stock by an insider. The filing lists 6003 shares of Common stock from Restricted Stock Units with an effective date of 07/01/2026. It also discloses recent 10b5-1 sales by Paul Lawrence Alpern of 6,500 shares on 07/01/2026 and 12,502 shares on 06/01/2026, with proceeds shown in the excerpt.
BAYVIEW LEGACY, LLC reported proposed sales of Common Stock of AIP under Rule 144 via 10b5-1 arrangements. The notice lists 181,338 shares on 07/01/2026 with proceeds of $8,243,335.34 and 192,686 shares on 07/02/2026 with proceeds of $6,998,663.82. The broker shown is Morgan Stanley Smith Barney LLC.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported multiple transactions in the company’s common stock on July 1, 2026. He sold a total of 6,500 shares in open-market transactions at weighted average prices ranging from about $43.70 to $47.50, carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised stock options to acquire 6,500 shares of common stock at exercise prices of $9.28 and $0.56 per share. Following these transactions, he continues to hold more than 80,000 shares of Arteris common stock directly.